Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2021-06-03 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Presentation - 4 June 2021 32 pages 2.5MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation | 4 June 2021' and contains detailed information about the company's clinical programs, financial position, capital structure, leadership team, pipeline, and anticipated news flow. It includes forward-looking statements, executive summary, cash and capital structure details, scientific leadership bios, clinical trial designs, and timelines for drug development milestones. The content is typical of a presentation aimed at investors to provide an overview of the company's strategy, financial health, and future prospects. There are no full financial statements or audit details, nor is it a transcript of a call or a regulatory filing. The length and detail confirm it is a presentation document rather than a brief announcement or report publication notice.
2021-06-03 English
Pharmaxis Investor Briefing 2 pages 140.2KB
Investor Presentation Classification · 90% confidence The document is a media release announcing an upcoming virtual investor briefing scheduled for June 4, 2021. It includes details about the event format (presentation followed by Q&A), registration instructions, and contact information. The content focuses on inviting investors and analysts to participate and does not contain any financial statements, detailed financial analysis, or substantive financial data. It is not a transcript of the briefing, nor is it a report or presentation itself. The document is relatively short (4813 characters) and serves as an announcement of an event rather than the event content or a financial report. Therefore, it fits best into the category of Investor Presentation (IP) announcements or invitations. However, since it is an announcement of the briefing rather than the presentation material itself, and given the definitions, the closest appropriate classification is Investor Presentation (IP) because the briefing is described as a presentation for investors focusing on company progress and plans, which aligns with the IP category. Confidence is high due to clear event invitation and description of presentation content without actual presentation data.
2021-05-30 English
Change of Director's Interest Notice 3 pages 150.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including on-market purchases and off-market transfers, with specific dates and share quantities. This matches the definition of a Director's Dealing report, which involves personal share transactions by company directors and executives. The document is not an announcement of a report, nor a full financial report, but a regulatory disclosure of insider trading activity.
2021-05-03 English
Promising New Drug to Tackle Brain Cancer 3 pages 137.3KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 3 May 2021 from Pharmaxis Ltd announcing a research grant from the Charlie Teo Foundation to study a new drug candidate for brain cancer. It discusses the drug's mechanism, ongoing and planned clinical trials, and background on the company and the foundation. There are no financial statements, regulatory certifications, voting results, or management changes. The content is a corporate announcement about a research collaboration and funding, not a financial report, earnings release, or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report. The document fits best as a general regulatory announcement or corporate news update that does not fit other categories, which corresponds to Regulatory Filings (RNS).
2021-05-02 English
Appendix 4C - quarterly 5 pages 185.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly cash flow report for entities subject to Listing Rule 4.7B'. It contains detailed cash flow statements for the quarter ended 31 March 2021, including operating, investing, and financing activities, with specific financial figures. The presence of quarterly financial data and the nature of the report align with an Interim / Quarterly Report. The document is substantive and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-04-29 English
Quarterly Activity Report 10 pages 495.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – March 2021' and contains detailed operational updates, clinical trial progress, drug development pipeline status, sales data, and capital raising information for the quarter ending March 2021. It includes substantive financial data such as sales figures for Bronchitol and Aridol products, milestone payments received, and capital raise details. The content is comprehensive and covers a period shorter than a full fiscal year, consistent with a quarterly report. There is no indication that this is merely an announcement or a presentation, nor is it a transcript or a regulatory filing of a different nature. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-29 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.